IVX: IVAX Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVX: IVAX Corporation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (73)	11/9/2005 1:00:38 PM
From: Jim Oravetz	Read Replies (1) of 78

IVAX 3Q Net Up 25% On Record Rev Of $617.7M DOW JONES NEWSWIRES November 8, 2005 9:22 a.m. MIAMI -- Ivax Corp.'s (IVX) third-quarter earnings rose 25%, as the company booked deferred revenue from a licensing agreement and North America sales jumped 39%. In a press release Tuesday, the Miami generic-drug maker said net income rose to $55.4 million, or 20 cents a share, from $44.4 million, or 17 cents a share, last year. The latest quarter included a charge of 4 cents a share related to the company's planned acquisition by Teva Pharmaceutical Industries Ltd. (TEVA). Revenue jumped 41% to $617.7 million from $439.1 million in the year-ago quarter. In North America, revenue rose to a quarterly record $295 million from $213 million. Analysts polled by Thomson First Call expected earnings of 22 cents a share on revenue of $569 million. First Call estimates typically exclude items.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next